Abstract
Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. We have previously shown that Apo2 ligand/TNF-Related apoptosis inducing ligand (Apo2L/TRAIL) induces apoptosis of MM cells, including cells either sensitive or resistant to Dex and cytotoxic drugs, and overcomes the growth and survival effect of IL-6; conversely, NF-κB transcriptional activity attenuates their Apo2L/TRAIL-sensitivity. In the current study, we demonstrate that IGF-1 stimulates sustained activation of NF-κB and Akt; induces phosphorylation of the FKHRL-1 Forkhead transcription factor; upregulates a series of intracellular anti-apoptotic proteins including FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP; and decreases Apo2L/TRAIL-sensitivity of MM cells. In contrast, IL-6 does not cause sustained NF-κB activation, induces less pronounced Akt activation and FKHRL-1 phosphorylation than IGF-1, and increases the expression of only survivin. Forced overexpression of constitutively active Akt in MM-1S cells reduced their sensitivity to Apo2L/TRAIL and to doxorubicin (Doxo). In contrast, the Akt inhibitor IL-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate induced cell death of both Dex- and Doxo-sensitive and -resistant cells; opposed the protective effect of constitutive Akt activity against Apo2L/TRAIL; and abrogated the NF-κB activation, increase of anti-apoptotic proteins and protection against Apo2L/TRAIL induced by IGF-1. These findings therefore define an important role of the Akt pathway in modulating tumor cell responsiveness to Apo2L/TRAIL, delineate molecular mechanisms for the survival effects of IGF-1, and characterize differential pathophysiologic sequelae of IGF-1 vs IL-6 on MM cells. Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . 1999 J. Clin. Invest. 104: 155–162
Burns TF, El-Deiry WS . 2001 J. Biol. Chem. 276: 37879–37886
Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC . 2002 Oncogene 21: 1346–1358
Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC . 2000 J. Biol. Chem. 275: 27845–27850
Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK . 2001 Oncogene 20: 6073–6083
Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW . 1997 Proc. Natl. Acad. Sci. USA 94: 10057–10062
Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS . 1999 Blood 93: 3044–3052
Ge NL, Rudikoff S . 2000 Blood 96: 2856–2861
Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K . 1996 Blood 88: 2250–2258
Grundker C, Schulz K, Gunthert AR, Emons G . 2000 J. Clin. Endocrinol. Metab. 85: 3815–3820
Han YP, Tuan TL, Wu H, Hughes M, Garner WL . 2001 J. Cell. Sci. 114: 131–139
Heck S, Lezoualc'h F, Engert S, Behl C . 1999 J. Biol. Chem. 274: 9828–9835
Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC . 2001a Oncogene 20: 4519–4527
Hideshima T, Nakamura N, Chauhan D, Anderson KC . 2001b Oncogene 20: 5991–6000
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP . 2000 J. Med. Chem. 43: 3045–3051
Jelinek DF, Witzig TE, Arendt BK . 1997 J. Immunol. 159: 487–496
Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP . 2002 FASEB J. 16: 438–440
Kane LP, Shapiro VS, Stokoe D, Weiss A . 1999 Curr. Biol. 9: 601–604
Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J . 1999 J. Immunol. 163: 590–598
Kreuz S, Siegmund D, Scheurich P, Wajant H . 2001 Mol. Cell. Biol. 21: 3964–3973
LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ . 1995 Ann. NY Acad. Sci. 766: 402–408
Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J . 1995 J. Biol. Chem. 270: 14255–14258
Mitsiades CS, Mitsiades NS, Anderson KC, Treon SP . 2001a Proc. Am. Assoc. Cancer Res. 42: 348
Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC . 2001b Blood 98: 795–804
Mitsiades CS, Treon SP, Mitsiades NS, Anderson KC . 2000 Blood 96: 3269
Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP . 2002a Blood 99: 2162–2171
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC . 2002b Blood 99: 4079–4086
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC . 2002c Blood 99: 4525–4530
Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS . 2001 J. Biol. Chem. 276: 10767–10774
Ogawa M, Nishiura T, Oritani K, Yoshida H, Yoshimura M, Okajima Y, Ishikawa J, Hashimoto K, Matsumura I, Tomiyama Y, Matsuzawa Y . 2000 Cancer Res. 60: 4262–4269
Panka D, Mano T, Suhara T, Walsh K, Mier JW . 2001 J. Biol. Chem. 276: 6893–6896
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . 1996 J. Biol. Chem. 271: 12687–12690
Pons S, Torres-Aleman I . 2000 J. Biol. Chem. 275: 38620–38625
Poulaki V, Mitsiades N, Romero ME, Tsokos M . 2001 Cancer Res. 61: 4864–4872
Powers C, Krutzsch H, Gardner K . 1996 J. Biol. Chem. 271: 30089–30095
Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, Chase TN . 1999 J. Neurosci. 19: 4023–4033
Qin ZH, Wang Y, Nakai M, Chase TN . 1998 Mol. Pharmacol. 53: 33–42
Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ . 2000 Cancer Res. 60: 2007–2017
Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK . 2001 J. Biol. Chem. 276: 38361–38369
Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS . 1999 Mol. Cell. Biol. 19: 5923–5929
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . 1998 Science 281: 1680–1683
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA . 1995 Immunity 3: 673–682
Xiao C, Ash K, Tsang B . 2001 Endocrinology 142: 557–563
Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A . 1997 Br. J. Haematol. 97: 429–440
Ye J, Ding M, Zhang X, Rojanasakul Y, Nedospasov S, Vallyathan V, Castranova V, Shi X . 1999 Mol. Cell. Biochem. 198: 193–200
Acknowledgements
This work was supported by the Multiple Myeloma Research Foundation (CS Mitsiades, N Mitsiades), Lauri Strauss Leukemia Foundation (CS Mitsiades, N Mitsiades), National Institutes of Health Grants RO-1 50947 and PO-1 78378, and the Doris Duke Distinguished Clinical Research Scientist Award (KC Anderson).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mitsiades, C., Mitsiades, N., Poulaki, V. et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21, 5673–5683 (2002). https://doi.org/10.1038/sj.onc.1205664
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205664
Keywords
This article is cited by
-
Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role
Medical Oncology (2023)
-
Pathophysiological role of calcium channels and transporters in the multiple myeloma
Cell Communication and Signaling (2021)
-
TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms
British Journal of Cancer (2021)
-
Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia
BMC Cancer (2017)
-
Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma
Journal of Experimental & Clinical Cancer Research (2017)